News
Clearside Biomedical
CLSD · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- NewsAvi Kapoor
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
- Press releaseGlobe Newswire
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
- NewsAvi Kapoor
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
- NewsAnthony Noto
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie
- Press releaseGlobe Newswire
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
- News
Earnings Scheduled For May 14, 2025
- News
A Peek at Clearside Biomedical's Future Earnings
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- News
Exploring Clearside Biomedical's Earnings Expectations
- News
Clearside Biomedical Highlights CLS-AX Presentation At 2025 Wet AMD & Diabetic Eye Disease Summit
- Press releaseGlobe Newswire
Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
- Press releaseGlobe Newswire
Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
- Press releaseGlobe Newswire
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
- News
Market-Moving News for October 9th
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.